Published in Acta Oncol on August 21, 2013
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol (2015) 0.89
Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Rep Pract Oncol Radiother (2015) 0.82
Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist (2014) 0.82
Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol (2014) 0.82
Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. J Radiat Res (2016) 0.81
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol (2015) 0.78
Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study. ScientificWorldJournal (2013) 0.78
Differential regulation of ferritin subunits and iron transport proteins: an effect of targeted hepatic X-irradiation. Biomed Res Int (2013) 0.77
Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer (2016) 0.76
Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol (2015) 0.76
Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol (2014) 0.76
Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med (2016) 0.75
Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int (2016) 0.75
Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol (2016) 0.75
Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol (2016) 0.75
Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer (2016) 0.75
Charged particle therapy for hepatocellular carcinoma: a commentary on a recently published meta-analysis. Ann Transl Med (2015) 0.75
Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol (2016) 0.75
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol (2016) 0.75
Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol (2017) 0.75
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol (2017) 0.75
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys (2007) 2.56
Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol (2011) 1.48
Development of realistic high-resolution whole-body voxel models of Japanese adult males and females of average height and weight, and application of models to radio-frequency electromagnetic-field dosimetry. Phys Med Biol (2004) 1.34
Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys (2008) 1.23
The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol (2011) 1.18
Dose distribution analysis of axillary lymph nodes for three-dimensional conformal radiotherapy with a field-in-field technique for breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.18
Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol (2006) 1.10
Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.09
Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol (2004) 1.07
Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatol Res (2007) 1.05
Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys (2009) 1.03
Evaluation of novel modified tangential irradiation technique for breast cancer patients using dose-volume histograms. Int J Radiat Oncol Biol Phys (2004) 1.02
Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. Lung Cancer (2012) 0.99
Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol (2014) 0.97
Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy--initial findings. Radiology (2005) 0.97
Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys (2009) 0.95
Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med (2008) 0.94
Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol (2014) 0.93
Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy. J Thorac Oncol (2014) 0.93
Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol (2011) 0.92
Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys (2005) 0.92
Pattern of tumor recurrence in initially nonmetastatic breast cancer patients: distribution and frequency of metastases at unusual sites. Cancer (2008) 0.92
Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys (2012) 0.89
Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys (2010) 0.89
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007]. Jpn J Antibiot (2009) 0.88
Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy? Clin Breast Cancer (2012) 0.87
Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol (2012) 0.87
Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer. Lung Cancer (2012) 0.87
Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg (2012) 0.87
Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol (2013) 0.86
Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 0.86
Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat Oncol Biol Phys (2009) 0.86
Differences in the definition of internal target volumes using slow CT alone or in combination with thin-slice CT under breath-holding conditions during the planning of stereotactic radiotherapy for lung cancer. Radiother Oncol (2007) 0.84
Re-irradiation for metastatic brain tumors with whole-brain radiotherapy. Jpn J Clin Oncol (2012) 0.84
Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens' antibacterial susceptibility. J Infect Chemother (2011) 0.83
[In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002]. Jpn J Antibiot (2005) 0.83
[A case of cutaneous Mycobacterium nonchromogenicum infection suggesting sarcoidosis association]. Kansenshogaku Zasshi (2010) 0.82
Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest (2013) 0.82
Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study. Radiat Oncol (2013) 0.82
Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats. Eur J Pharm Biopharm (2011) 0.81
Converging stereotactic radiotherapy using kilovoltage X-rays: experimental irradiation of normal rabbit lung and dose-volume analysis with Monte Carlo simulation. Int J Radiat Oncol Biol Phys (2009) 0.81
Partial splenic embolization reverses insulin resistance in patients with liver cirrhosis. Intern Med (2009) 0.81
Treatment of breast carcinoma in patients with clinically negative axillary lymph nodes using radiotherapy versus axillary dissection. Cancer (2004) 0.81
Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis: multicenter study. J Gastroenterol (2002) 0.81
Characteristics of bacterial species in positive blood cultures among hospitalized patients in three wards in the Department of Internal Medicine: retrospective chart review 1999-2008. Intern Med (2012) 0.80
Proportion-corrected scaled voxel models for Japanese children and their application to the numerical dosimetry of specific absorption rate for frequencies from 30 MHz to 3 GHz. Phys Med Biol (2008) 0.80
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. Int J Radiat Oncol Biol Phys (2009) 0.80
[Locally advanced granulocyte colony-stimulating factor-producing non-small cell lung cancer successfully treated with concurrent chemoradiotherapy]. Gan To Kagaku Ryoho (2013) 0.79
Dose calculation with a cone beam CT image in image-guided radiation therapy. Radiol Phys Technol (2012) 0.79
Experimental stereotactic irradiation of normal rabbit lung: computed tomographic analysis of radiation injury and the histopathological features. Radiat Med (2007) 0.79
Intra-arterial CT-angiography for cerebral arteriovenous malformation--initial experiences for treatment planning of radiosurgery. Int J Radiat Oncol Biol Phys (2002) 0.79
Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res (2014) 0.79
Value of CT thallium-201 SPECT fusion imaging over SPECT alone for detection and localization of nasopharyngeal and maxillary cancers. AJR Am J Roentgenol (2006) 0.78
[Quantitative Bayesian diagnosis developed for lower respiratory tract infections due to methicillin-resistant Staphylococcus aureus]. Kansenshogaku Zasshi (2010) 0.78
Biodistribution of immunoliposome labeled with Tc-99m in tumor xenografted mice. Ann Nucl Med (2009) 0.78
Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides (2009) 0.78
Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results. Oncol Lett (2011) 0.78